Haemonetics Posts $358M in Q2 Revenue
HAE has more than doubled off its 52-week low of $49.96.
Summary
Haemonetics reported second-quarter revenue of $358 million, with adjusted EPS of $1.35 and EPS of $1. That compares with $339.4 million in the prior quarter (fiscal Q1 2027), which itself grew 5.6% year over year. The headline gives no year-ago comparison or margin figure, so the growth rate and profitability picture are not yet clear. The stock sits near its 52-week high of $128.83, so expectations are already elevated heading into this print.
At the time of this announcement, HAE was trading at $127.42 on NYSE in the Life Sciences sector, with a market capitalization of approximately $5.8B. The 52-week trading range was $49.96 to $128.83. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.